CleanSpark, Inc. (NASDAQ: CLSK) shares jumped Thursday despite analyst downgrades. The company’s stock rose 5.2% to $10.39 on April 9, 2026, even as two Wall Street firms adjusted their outlook on the name, with volume reaching 16.7M shares.
Cantor Fitzgerald cut its price target while maintaining conviction. The firm lowered its target to $14 from $17 but kept an Overweight rating on CleanSark, signaling continued confidence in the stock’s upside potential despite the reduced forecast. Chardan Capital maintained its Buy rating and $16 price target unchanged, providing a vote of stability amid the reassessment.
The market looked past the downgrade math. While the average new price target stands at $15 across both firms, representing a downward revision, investors appeared to focus on the maintained Buy-equivalent ratings rather than the target adjustments. The $2.7B market cap company saw its shares rally despite what would typically be considered negative analyst action, suggesting underlying momentum or positioning ahead of upcoming catalysts.
CleanSpark’s counterintuitive move reflects complex market dynamics. Stocks don’t always trade on the obvious headline, and Thursday’s session proved that point. The maintained Overweight and Buy ratings from both firms may have overshadowed the target cut, or traders could be positioning for developments not yet reflected in analyst models. The elevated volume suggests institutional participation in the move, not just retail enthusiasm.
Technical traders may be driving the action. With both analysts still projecting upside from the current $10.39 price level, the stock’s rally could reflect recognition that even the reduced $14 target from Cantor Fitzgerald implies significant gains. The Chardan Capital $16 target represents even more substantial upside, potentially drawing in momentum players.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.